4.7 Article

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility

Journal

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 60, Issue 5, Pages 3174-3177

Publisher

AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.03029-15

Keywords

-

Funding

  1. Achaogen
  2. Actavis
  3. Actelion
  4. Allergan
  5. American Proficiency Institute (API)
  6. AmpliPhi
  7. Anacor
  8. Astellas
  9. AstraZeneca
  10. Basilea
  11. Bayer
  12. BD
  13. Cardeas
  14. Cellceutix
  15. CEM-102 Pharmaceuticals
  16. Cempra
  17. Cerexa
  18. Cidara
  19. Cormedix
  20. Cubist
  21. Debiopharm
  22. Dipexium
  23. Dong Wha
  24. Durata
  25. Enteris
  26. Exela
  27. Forest Research Institute
  28. Furiex
  29. Genentech
  30. GSK
  31. Helperby
  32. ICPD
  33. Janssen
  34. Lannett
  35. Longitude
  36. Medpace
  37. Meiji Seika Kasha
  38. Melinta
  39. Merck
  40. Motif
  41. Nabriva
  42. Novartis
  43. Paratek
  44. Pfizer
  45. Pocared
  46. PTC Therapeutics
  47. Rempex
  48. Roche
  49. Salvat
  50. Scynexis
  51. Seachaid
  52. Shionogi
  53. Tetraphase
  54. Medicines Co.
  55. Theravance
  56. ThermoFisher
  57. VenatoRX
  58. Vertex
  59. Wockhardt
  60. Zavante

Ask authors/readers for more resources

Measurement of vancomycin susceptibility has been shown to be highly predictive as a surrogate measure of oritavancin susceptibility among clinically indicated Gram-positive species. Results of studying over 30,000 pathogens (from 2011 to 2014) by cross-susceptibility analysis and determining the poor reproducibility of oritavancin-nonsusceptible results showed nearly perfect surrogate testing accuracy (99.86 to 99.94%). Any isolate of an indicated organism species with locally reproducible oritavancin- nonsusceptible results (extremely rare) should be referred to a reference laboratory for confirmation of the results and determination of the resistance mechanism.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available